INTERVIEW: Roche's Dan Chen Talks Immuno-Oncology Combinations

The head of Roche/Genentech's immuno-oncology programs discussed the firm's combination strategy at the recent American Society of Clinical Oncology annual meeting in Chicago.

The well-established leader in oncology, Roche has taken an unaccustomed back seat in the emerging field of cancer immunotherapy. But with nine immuno-oncology assets in the clinic and its PD-L1 inhibitor Tecentriq (atezolizumab) clearing FDA a couple weeks before ASCO, the time has come for Roche to make its mark, especially as Tecentriq is the first PD-L1 inhibitor and the first IO therapy for bladder cancer. (Also see "Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market" - Scrip, 19 May, 2016.) Global Head of Cancer Immunotherapy Dan Chen explained Roche's strategy on combinations and how the firm plans to uphold its leadership position.

Q: It's only been a week, but are there early signs of how the Tecentriq launch is going?

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip